The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.
Nanomedicine Tumor Targeting
Open accessAbstract
Nanomedicines are extensively explored for cancer therapy. By delivering drug molecules more efficiently to pathological sites and by attenuating their accumulation in healthy organs and tissues, nanomedicine formulations aim to improve the balance between drug efficacy and toxicity. More than 20 cancer nanomedicines are approved for clinical use, and hundreds of formulations are in (pre)clinical development. Over the years, several key pitfalls have been identified as bottlenecks in nanomedicine tumor targeting and translation. These go beyond materials‐ and production‐related issues, and particularly also encompass biological barriers and pathophysiological heterogeneity. In this manuscript, the author describes the most important principles, progress, and products in nanomedicine tumor targeting, delineates key current problems and challenges, and discusses the most promising future prospects to create clinical impact.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Block copolymer micelles for drug delivery: design, characterization and biological significance
Kataoka, K., Harada, A., & Nagasaki, Y. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00124-1 · Cited by 3,506
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Polymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
The entry of nanoparticles into solid tumours
Sindhwani, S., Syed, A. M., Ngai, J., Kingston, B. R., Maiorino, L., Rothschild, J., MacMillan, P., Zhang, Y., Rajesh, N. U., Hoang, T., et al. (2020) · Nature Materials · doi:10.1038/s41563-019-0566-2 · Cited by 1,732
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
CAR T cells produced in vivo to treat cardiac injury
Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2022) · Science · doi:10.1126/science.abm0594 · Cited by 1,400
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Self-citationBlock copolymer micelles in nanomedicine applications
Cabral, H., Miyata, K., Osada, K., & Kataoka, K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00199 · Cited by 1,309
Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F., Mulder, W. J. M., & Lammers, T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0567-y · Cited by 1,234
Self-citationWang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00986-1 · Cited by 1,222
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Self-citationTrastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Cortés, J., Kim, S.-B., Chung, W.-P., Im, S.-A., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L.-M., Petry, V., Chung, C.-F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115022 · Cited by 1,175
Hrkach, J., Von Hoff, D., Ali, M. M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003651 · Cited by 1,147
Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,125
Chauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Davis, M. E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900015y · Cited by 977
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system
Sengupta, S., Eavarone, D., Capila, I., Zhao, G., Watson, N., Kiziltepe, T., & Sasisekharan, R. (2005) · Nature · doi:10.1038/nature03794 · Cited by 945
CAR T Cells Produced in vivo to Treat Cardiac Injury
Rurik, J. G., Tombácz, I., Yadegari, A., Fernández, P. O. M., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2023) · HAL · Cited by 926
Voorwerk, L., Slagter, M., Horlings, H. M., Sikorska, K., van de Vijver, K. K., de Maaker, M., Nederlof, I., Kluin, R. J. C., Warren, S., Ong, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0432-4 · Cited by 905
Meng, H., Liong, M., Xia, T., Li, Z., Ji, Z., Zink, J. I., & Nel, A. E. (2010) · ACS Nano · doi:10.1021/nn100690m · Cited by 902
Enhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 882
Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
Antibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Understanding ultrasound induced sonoporation: Definitions and underlying mechanisms
Lentacker, I., De Cock, I., Deckers, R., De Smedt, S. C., & Moonen, C. T. W. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.008 · Cited by 815
Strategies for advancing cancer nanomedicine
Chauhan, V. P., & Jain, R. K. (2013) · Nature Materials · doi:10.1038/nmat3792 · Cited by 812
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N. (2016) · Science · doi:10.1126/science.aaf2834 · Cited by 748
Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733
Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles
Choi, C. H. J., Alabi, C. A., Webster, P., & Davis, M. E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914140107 · Cited by 699
Hurvitz, S. A., Hegg, R., Chung, W.-P., Im, S.-A., Jacot, W., Ganju, V., Chiu, J. W. Y., Xu, B., Hamilton, E., Madhusudan, S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02420-5 · Cited by 687
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 682
Microvascular permeability of normal and neoplastic tissues
Gerlowski, L. E., & Jain, R. K. (1986) · Microvascular Research · doi:10.1016/0026-2862(86)90018-x · Cited by 622
Meng, H., Mai, W. X., Zhang, H., Xue, M., Xia, T., Lin, S., Wang, X., Zhao, Y., Ji, Z., Zink, J. I., et al. (2013) · ACS Nano · doi:10.1021/nn3044066 · Cited by 575
HPMA copolymer–anticancer drug conjugates: design, activity, and mechanism of action
Kopecek, J. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00075-8 · Cited by 562
Tumour-targeted nanomedicines: principles and practice
Lammers, T., Hennink, W. E., & Storm, G. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604483 · Cited by 542
Self-citationBonvalot, S., Rutkowski, P. L., Thariat, J., Carrère, S., Ducassou, A., Sunyach, M.-P., Agoston, P., Hong, A., Mervoyer, A., Rastrelli, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30326-2 · Cited by 536
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
Martin, J. D., Seano, G., & Jain, R. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114700 · Cited by 530
Murphy, J. E., Wo, J. Y., Ryan, D. P., Clark, J. W., Jiang, W., Yeap, B. Y., Drapek, L. C., Ly, L., Baglini, C. V., Blaszkowsky, L. S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0892 · Cited by 522
The dose threshold for nanoparticle tumour delivery
Ouyang, B., Poon, W., Zhang, Y.-N., Lin, Z. P., Kingston, B. R., Tavares, A. J., Zhang, Y., Chen, J., Valic, M. S., Syed, A. M., et al. (2020) · Nature Materials · doi:10.1038/s41563-020-0755-z · Cited by 514
The landscape of mRNA nanomedicine
Huang, X., Kong, N., Zhang, X., Cao, Y., Langer, R., & Tao, W. (2022) · Nature Medicine · doi:10.1038/s41591-022-02061-1 · Cited by 511
Comprehensive analysis of the clinical immuno-oncology landscape
Tang, J., Shalabi, A., & Hubbard-Lucey, V. M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx755 · Cited by 508
Combining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508
Talelli, M., Barz, M., Rijcken, C. J. F., Kiessling, F., Hennink, W. E., & Lammers, T. (2015) · Nano Today · doi:10.1016/j.nantod.2015.01.005 · Cited by 506
Self-citationManzoor, A. A., Lindner, L. H., Landon, C. D., Park, J.-Y., Simnick, A. J., Dreher, M. R., Das, S., Hanna, G., Park, W., Chilkoti, A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1683 · Cited by 459
Combining Nanomedicine and Immunotherapy
Shi, Y., & Lammers, T. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00148 · Cited by 457
Self-citationTherapeutic targeting of trained immunity
Mulder, W. J. M., Ochando, J., Joosten, L. A. B., Fayad, Z. A., & Netea, M. G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0025-4 · Cited by 443
Tumour‐associated macrophages act as a slow‐release reservoir of nano‐therapeutic Pt(IV) pro‐drug
Miller, M. A., Zheng, Y.-R., Gadde, S., Pfirschke, C., Zope, H., Engblom, C., Kohler, R. H., Iwamoto, Y., Yang, K. S., Askevold, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms9692 · Cited by 441
Hennrich, U., & Kopka, K. (2019) · Pharmaceuticals · doi:10.3390/ph12030114 · Cited by 440
Lu, J., Liu, X., Liao, Y.-P., Salazar, F., Sun, B., Jiang, W., Chang, C. H., Jiang, J., Wang, X., Wu, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01651-9 · Cited by 440
Poly(l-glutamic acid)–anticancer drug conjugates
Li, C. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00045-5 · Cited by 414
Cellular backpacks for macrophage immunotherapy
Shields, C. W., Evans, M. A., Wang, L. L.-W., Baugh, N., Iyer, S., Wu, D., Zhao, Z., Pusuluri, A., Ukidve, A., Pan, D. C., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6579 · Cited by 414
Challenges in nanomedicine clinical translation
Metselaar, J. M., & Lammers, T. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00740-5 · Cited by 396
Self-citationLee, H., Shields, A. F., Siegel, B. A., Miller, K. D., Krop, I., Ma, C. X., LoRusso, P. M., Munster, P. N., Campbell, K., Gaddy, D. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3193 · Cited by 393
The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
Tang, J., Yu, J. X., Hubbard-Lucey, V. M., Neftelinov, S. T., Hodge, J. P., & Lin, Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.210 · Cited by 382
Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics
Baxter, L. T., & Jain, R. K. (1990) · Microvascular Research · doi:10.1016/0026-2862(90)90023-k · Cited by 363
Grüll, H., & Langereis, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.041 · Cited by 360
Tardi, P., Johnstone, S., Harasym, N., Xie, S., Harasym, T., Zisman, N., Harvie, P., Bermudes, D., & Mayer, L. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.06.028 · Cited by 356
Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions
Anchordoquy, T. J., Barenholz, Y., Boraschi, D., Chorny, M., Decuzzi, P., Dobrovolskaia, M. A., Farhangrazi, Z. S., Farrell, D., Gabizon, A., Ghandehari, H., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b08244 · Cited by 337
Nanoparticles in the clinic: An update post COVID‐19 vaccines
Anselmo, A. C., & Mitragotri, S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10246 · Cited by 337
Current approaches of nanomedicines in the market and various stage of clinical translation
Shan, X., Gong, X., Li, J., Wen, J., Li, Y., & Zhang, Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.025 · Cited by 335
Mayer, L. D., Harasym, T. O., Tardi, P. G., Harasym, N. L., Shew, C. R., Johnstone, S. A., Ramsay, E. C., Bally, M. B., & Janoff, A. S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0118 · Cited by 331
Dinndorf, P. A., Gootenberg, J., Cohen, M. H., Keegan, P., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-991 · Cited by 324
Collagenase Nanoparticles Enhance the Penetration of Drugs into Pancreatic Tumors
Zinger, A., Koren, L., Adir, O., Poley, M., Alyan, M., Yaari, Z., Noor, N., Krinsky, N., Simon, A., Gibori, H., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b02395 · Cited by 323
A modular platform for targeted RNAi therapeutics
Kedmi, R., Veiga, N., Ramishetti, S., Goldsmith, M., Rosenblum, D., Dammes, N., Hazan-Halevy, I., Nahary, L., Leviatan-Ben-Arye, S., Harlev, M., et al. (2018) · Nature Nanotechnology · doi:10.1038/s41565-017-0043-5 · Cited by 320
Passive versus Active Tumor Targeting Using RGD- and NGR-Modified Polymeric Nanomedicines
Kunjachan, S., Pola, R., Gremse, F., Theek, B., Ehling, J., Moeckel, D., Hermanns-Sachweh, B., Pechar, M., Ulbrich, K., Hennink, W. E., et al. (2014) · Nano Letters · doi:10.1021/nl404391r · Cited by 317
Self-citationOpacic, T., Dencks, S., Theek, B., Piepenbrock, M., Ackermann, D., Rix, A., Lammers, T., Stickeler, E., Delorme, S., Schmitz, G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03973-8 · Cited by 295
Self-citation64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
Tamura, K., Kurihara, H., Yonemori, K., Tsuda, H., Suzuki, J., Kono, Y., Honda, N., Kodaira, M., Yamamoto, H., Yunokawa, M., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.118612 · Cited by 294
Von Hoff, D. D., Mita, M. M., Ramanathan, R. K., Weiss, G. J., Mita, A. C., LoRusso, P. M., Burris, H. A., Hart, L. L., Low, S. C., Parsons, D. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2548 · Cited by 286
Autio, K. A., Dreicer, R., Anderson, J., Garcia, J. A., Alva, A., Hart, L. L., Milowsky, M. I., Posadas, E. M., Ryan, C. J., Graf, R. P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2168 · Cited by 275
Ojha, T., Pathak, V., Shi, Y., Hennink, W. E., Moonen, C. T. W., Storm, G., Kiessling, F., & Lammers, T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.007 · Cited by 260
Self-citationZhao, Y., Cao, J., Melamed, A., Worley, M., Gockley, A., Jones, D., Nia, H. T., Zhang, Y., Stylianopoulos, T., Kumar, A. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818357116 · Cited by 259
Novel Temperature-Sensitive Liposomes with Prolonged Circulation Time
Lindner, L. H., Eichhorn, M. E., Eibl, H., Teichert, N., Schmitt-Sody, M., Issels, R. D., & Dellian, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0035 · Cited by 258
Lammers, T., Subr, V., Ulbrich, K., Peschke, P., Huber, P. E., Hennink, W. E., & Storm, G. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.02.040 · Cited by 240
Self-citationCancer nanomedicine: is targeting our target?
Lammers, T., Kiessling, F., Ashford, M., Hennink, W., Crommelin, D., & Storm, G. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.69 · Cited by 233
Self-citationLyon, P. C., Gray, M. D., Mannaris, C., Folkes, L. K., Stratford, M., Campo, L., Chung, D. Y. F., Scott, S., Anderson, M., Goldin, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30332-2 · Cited by 233
Priem, B., van Leent, M. M. T., Teunissen, A. J. P., Sofias, A. M., Mourits, V. P., Willemsen, L., Klein, E. D., Oosterwijk, R. S., Meerwaldt, A. E., Munitz, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.059 · Cited by 222
To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes
Dou, Y., Hynynen, K., & Allen, C. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.025 · Cited by 210
Cell‐Based Drug Delivery Devices Using Phagocytosis‐Resistant Backpacks
Doshi, N., Swiston, A. J., Gilbert, J. B., Alcaraz, M. L., Cohen, R. E., Rubner, M. F., & Mitragotri, S. (2011) · Advanced Materials · doi:10.1002/adma.201004074 · Cited by 191
Panagi, M., Voutouri, C., Mpekris, F., Papageorgis, P., Martin, M. R., Martin, J. D., Demetriou, P., Pierides, C., Polydorou, C., Stylianou, A., et al. (2020) · Theranostics · doi:10.7150/thno.36936 · Cited by 191
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Wagner, A. J., Ravi, V., Riedel, R. F., Ganjoo, K., Van Tine, B. A., Chugh, R., Cranmer, L., Gordon, E. M., Hornick, J. L., Du, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01728 · Cited by 183
Nagamitsu, A., Greish, K., & Maeda, H. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp074 · Cited by 180
Polymeric Nanoparticles with Neglectable Protein Corona
Alberg, I., Kramer, S., Schinnerer, M., Hu, Q., Seidl, C., Leps, C., Drude, N., Möckel, D., Rijcken, C., Lammers, T., et al. (2020) · Small · doi:10.1002/smll.201907574 · Cited by 173
Self-citationThe exit of nanoparticles from solid tumours
Nguyen, L. N. M., Lin, Z. P., Sindhwani, S., MacMillan, P., Mladjenovic, S. M., Stordy, B., Ngo, W., & Chan, W. C. W. (2023) · Nature Materials · doi:10.1038/s41563-023-01630-0 · Cited by 172
Sonoporation enhances liposome accumulation and penetration in tumors with low EPR
Theek, B., Baues, M., Ojha, T., Möckel, D., Veettil, S. K., Steitz, J., van Bloois, L., Storm, G., Kiessling, F., & Lammers, T. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.021 · Cited by 170
Self-citationTak, W. Y., Lin, S.-M., Wang, Y., Zheng, J., Vecchione, A., Park, S. Y., Chen, M. H., Wong, S., Xu, R., Peng, C.-Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2433 · Cited by 167
Guo, S., Lin, C. M., Xu, Z., Miao, L., Wang, Y., & Huang, L. (2014) · ACS Nano · doi:10.1021/nn5010815 · Cited by 164
Micro-CT Imaging of Tumor Angiogenesis
Ehling, J., Theek, B., Gremse, F., Baetke, S. C., Möckel, D., Maynard, J., Ricketts, S., Grüll, H., Neeman, M., Knuechel, R., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.10.014 · Cited by 157
Self-citationCole, C., Qiao, J., Kottke, T. J., Díaz, R. M., Ahmed, A. U., Sanchez-Perez, L. A., Brunn, G. J., Thompson, J., Chester, J. D., & Vile, R. G. (2005) · Nature Medicine · doi:10.1038/nm1297 · Cited by 148
Bort, G., Lux, F., Dufort, S., Crémillieux, Y., Verry, C., & Tillement, O. (2020) · Theranostics · doi:10.7150/thno.37543 · Cited by 147
Verry, C., Dufort, S., Lemasson, B., Grand, S., Pietras, J., Troprés, I., Crémillieux, Y., Lux, F., Mériaux, S., Larrat, B., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay5279 · Cited by 146
Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy
Lammers, T., Šubr, V., Peschke, P., Kühnlein, R., Hennink, W. E., Ulbrich, K., Kiessling, F. M., Heilmann, M., Debus, J., Huber, P. E., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604561 · Cited by 141
Self-citationMünster, P. N., Krop, I. E., LoRusso, P. M., Ma, C. X., Siegel, B. A., Shields, A. F., Molnár, I., Wickham, T. J., Reynolds, J. G., Campbell, K., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0235-2 · Cited by 139
Chattopadhyay, N., Cai, Z., Pignol, J., Keller, B. M., Lechtman, E., Bendayan, R., & Reilly, R. M. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100207t · Cited by 137
Lammers, T. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.028 · Cited by 135
Self-citationIntrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy
Talelli, M., Oliveira, S., Rijcken, C. J. F., Pieters, E. H. E., Etrych, T., Ulbrich, K., van Nostrum, R., Storm, G., Hennink, W. E., & Lammers, T. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.064 · Cited by 132
Self-citationRadiotheranostics in oncology: Making precision medicine possible
Aboagye, E. O., Barwick, T. D., & Haberkorn, U. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21768 · Cited by 131
Snipstad, S., Sulheim, E., Davies, C. D. L., MOONEN, C. T. W., Storm, G., Kiessling, F. M., Schmid, R., & Lammers, T. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1547279 · Cited by 131
Self-citationKoukouraki, A. M. I. K. S. (2000) · Acta Oncologica · doi:10.1080/028418600430789 · Cited by 128
Macrophages Actively Transport Nanoparticles in Tumors After Extravasation
Lin, Z. P., Nguyen, L. N. M., Ouyang, B., MacMillan, P., Ngai, J., Kingston, B. R., Mladjenovic, S. M., & Chan, W. C. W. (2022) · ACS Nano · doi:10.1021/acsnano.1c11578 · Cited by 127
Alfayez, M., Kantarjian, H. M., Kadia, T. M., Ravandi‐Kashani, F., & Daver, N. G. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1660970 · Cited by 121
Tumor Targeting by αvβ3-Integrin-Specific Lipid Nanoparticles Occurs via Phagocyte Hitchhiking
Sofias, A. M., Toner, Y. C., Meerwaldt, A. E., van Leent, M. M. T., Soultanidis, G. M., Elschot, M., Gonai, H., Grendstad, K., Flobak, Å., Neckmann, U., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b08693 · Cited by 121
Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma
Detappe, A., Nguyen, H. V. ‐., Jiang, Y., Agius, M. P., Wang, W., Mathieu, C., Su, N. K., Kristufek, S. L., Lundberg, D. J., Bhagchandani, S. H., et al. (2023) · Nature Nanotechnology · doi:10.1038/s41565-022-01310-1 · Cited by 116
Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients
van der Veldt, A. A. M., Hendrikse, N. H., Smit, E. F., Mooijer, M. P. J., Rijnders, A. Y., Gerritsen, W. R., van der Hoeven, J. J. M., Windhorst, A. D., Lammertsma, A. A., & Lubberink, M. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1489-y · Cited by 111
Gray, M. D., Lyon, P. C., Mannaris, C., Folkes, L. K., Stratford, M. R. L., Campo, L., Chung, D. Y. F., Scott, S., Anderson, M. C., Goldin, R. D., et al. (2019) · Radiology · doi:10.1148/radiol.2018181445 · Cited by 108
Turning down the heat: The case for mild hyperthermia and thermosensitive liposomes
Regenold, M., Bannigan, P., Evans, J. C., Waspe, A. C., Temple, M. J., & Allen, C. J. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102484 · Cited by 103
Islam, W., Fang, J. Q., Imamura, T., Etrych, T., Šubr, V., Ulbrich, K., & Maeda, H. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0696 · Cited by 101
Theek, B., Gremse, F., Kunjachan, S., Fokong, S., Pola, R., Pechar, M., Deckers, R., Storm, G., Ehling, J., Kiessling, F. M., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.007 · Cited by 100
Self-citationGasselhuber, A., Dreher, M. R., Rattay, F., Wood, B. J., & Haemmerich, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047453 · Cited by 99
Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies
Weinstein, S., Toker, I. A., Emmanuel, R., Ramishetti, S., Hazan‐Halevy, I., Rosenblum, D., Goldsmith, M., Avigdor, A., Benjamini, O., Bairey, O., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519273113 · Cited by 97
Wu, J., Tang, C., & Yin, C. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.10.012 · Cited by 92
Tsvetkova, Y., Beztsinna, N., Baues, M., Klein, D. C. G., Rix, A., Golombek, S. K., Rawashdeh, W. A., Gremse, F., Barz, M., Koynov, K., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b01171 · Cited by 86
Self-citationHarasym, T. O., Tardi, P. G., Harasym, N. L., Harvie, P., Johnstone, S. A., & Mayer, L. D. (2006) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/000000006783980937 · Cited by 84
Luo, J., Liu, R., Chen, F., Zhang, J., Zheng, S.-J., Shao, D., & Du, J. (2023) · ACS Nano · doi:10.1021/acsnano.2c08240 · Cited by 84
Shaikh, I. M., Tan, K.-B., Chaudhury, A., Liu, Y., Tan, B.-J., Tan, B. M. J., & Chiu, G. N. C. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.10.025 · Cited by 83
van der Veldt, A. A. M., Lubberink, M., Mathijssen, R. H. J., Loos, W. J., Herder, G. J. M., Greuter, H. N. J. M., Comans, E. F. I., Rutten, H. B., Eriksson, J., Windhorst, A. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3779 · Cited by 76
PET‐CT Imaging of Polymeric Nanoparticle Tumor Accumulation in Patients
Miedema, I. H. C., Zwezerijnen, G. J. C., Huisman, M. C., Doeleman, E., Mathijssen, R. H. J., Lammers, T., Hu, Q., van Dongen, G. A. M. S., Rijcken, C. J. F., Vugts, D. J., et al. (2022) · Advanced Materials · doi:10.1002/adma.202201043 · Cited by 71
Self-citationHPMA copolymers: 30years of advances☆
Lammers, T., & Ulbrich, K. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.12.004 · Cited by 70
Self-citationJayapaul, J., Hodenius, M., Arns, S., Lederle, W., Lammers, T., Comba, P., Kiessling, F. M., & Gätjens, J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.056 · Cited by 69
Self-citationFang, J. Q., Islam, R., Islam, W., Yin, H., Šubr, V., Etrych, T., Ulbrich, K., & Maeda, H. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070343 · Cited by 66
Co-delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy
Zhou, Q., Li, Y., Zhu, Y., Yu, C., Jia, H., Bao, B., Hu, H., Xiao, C., Zhang, J., Zeng, X., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.026 · Cited by 64
What Do We Mean When We Say Nanomedicine?
Liz‐Marzán, L. M., Nel, A. E., Brinker, C. J., Chan, W. C. W., Chen, C., Chen, X., Ho, D., Hu, Y., Kataoka, K., Kotov, N. A., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c08675 · Cited by 60
Tumor perfusion imaging predicts the intra-tumoral accumulation of liposomes
Stapleton, S., Allen, C. J., Pintilie, M., & Jaffray, D. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.08.296 · Cited by 55
Seki, T., Carroll, F., Illingworth, S., Green, N., Cawood, R., Bachtarzi, H., Šubr, V., Fisher, K. D., & Seymour, L. W. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.022 · Cited by 53
A modular approach toward producing nanotherapeutics targeting the innate immune system
van Leent, M. M. T., Meerwaldt, A. E., Berchouchi, A., Toner, Y. C., Burnett, M. E., Klein, E. D., Verschuur, A. V. D., Nauta, S. A., Munitz, J., Prévot, G., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe7853 · Cited by 52
Hu, Q., Rijcken, C. J. F., van Gaal, E. V. B., Brundel, P., Kostková, H., Etrych, T., Weber, B., Barz, M., Kiessling, F. M., Prakash, J., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.012 · Cited by 49
Self-citationLiang, C., Bai, X., Qi, C., Sun, Q., Han, X., Lan, T., Zhang, H., Zheng, X., Liang, R., Jiao, J., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120432 · Cited by 49
Self-citationA backpack-based myeloid cell therapy for multiple sclerosis
Kapate, N., Dunne, M., Kumbhojkar, N., Prakash, S., Wang, L., Graveline, A. R., Park, K. S., Suja, V. C., Goyal, J., Clegg, J. R., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221535120 · Cited by 49
Lencioni, R. A., & Cioni, D. (2016) · Hepatic Oncology · doi:10.2217/hep-2016-0005 · Cited by 45
Sadeghi, N., Deckers, R., Ozbakir, B., Akthar, S., Kok, R. J., Lammers, T., & Storm, G. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.11.002 · Cited by 44
Self-citationPolymer Therapeutics Designed for a Combination Therapy of Hormone‐Dependent Cancer
Vicent, M. J., Greco, F., Nicholson, R. I., Paul, A., Griffiths, P. C., & Duncan, R. (2005) · Angewandte Chemie · doi:10.1002/ange.200462960 · Cited by 43
Hyperthermia-induced doxorubicin delivery from thermosensitive liposomes via MR-HIFU in a pig model
Sebeke, L. C., Gómez, J. D. C., Heijman, E., Rademann, P., Simon, A. C., Ekdawi, S. N., Vlachakis, S., Toker, D., Mink, B. L., Schubert-Quecke, C., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.003 · Cited by 40
Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles
Rijcken, C. J. F., Lorenzi, F. D., Biancacci, I., Hanssen, R., Thewissen, M. M., Hu, Q., Atrafi, F., Liskamp, R. M. J., Mathijssen, R. H. J., Miedema, I. H. C., et al. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114613 · Cited by 39
Self-citationMacro-nanomedicine: Targeting the big picture
Lammers, T. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.11.031 · Cited by 32
Self-citationSpiers, L., Gray, M. D., Lyon, P. C., Sivakumar, S., Bekkali, N. L. H., Scott, S., Collins, L., Carlisle, R. C., Wu, F., Middleton, M. R., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11228-z · Cited by 31
Sofias, A. M., & Lammers, T. (2023) · Nature Nanotechnology · doi:10.1038/s41565-022-01265-3 · Cited by 28
Self-citationLokerse, W. J. M., Lazarian, A., Kleinhempel, A., Petrini, M., Schwarz, P. M., Hossann, M., Holdt, L. M., Mailänder, V., & Lindner, L. H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.014 · Cited by 23
Lammers, T., Šubr, V., Ulbrich, K., Peschke, P., Huber, P. E., Hennink, W. E., Storm, G., & Kiessling, F. M. (2010) · Nanomedicine · doi:10.2217/nnm.10.130 · Cited by 21
Self-citationDarguzyte, M., Holm, R., Baier, J., Drude, N., Schultze, J., Koynov, K., Schwiertz, D., Dadfar, S. M., Lammers, T., Barz, M., et al. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00593 · Cited by 19
Self-citationUltrasound-directed enzyme-prodrug therapy (UDEPT) using self-immolative doxorubicin derivatives
Roemhild, K., Besse, H. C., Wang, B., Peña, Q., Sun, Q., Omata, D., Ozbakir, B., Bos, C., Scheeren, H. W., Storm, G., et al. (2022) · Theranostics · doi:10.7150/thno.69168 · Cited by 18
Self-citationBecker, S., Momoh, J., Biancacci, I., Möckel, D., Wang, Q., May, J., Su, H., Candels, L. S., Berres, M., Kiessling, F. M., et al. (2023) · Small · doi:10.1002/smll.202208042 · Cited by 17
Self-citationLammers, T. (2020) · Nature Materials · doi:10.1038/s41563-020-00855-7 · Cited by 14
Self-citationClinical translation of radiotheranostics for precision oncology
Zhang, J., Zhao, T., Jakobsson, V., & Chen, X. S. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00106-9 · Cited by 14
Transformative Materials for Interfacial Drug Delivery
Desai, P. B., Dasgupta, A., Sofias, A. M., Peña, Q., Göstl, R., Slabu, I., Schwaneberg, U., Stiehl, T., Wagner, W., Jockenhoevel, S., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301062 · Cited by 10
Self-citationNanomedicine on the move: from monotherapeutic regimens to combination therapies
Lammers, T. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.3 · Cited by 5
Self-citation
Cited by
Zhang, J., Lu, L., Zhang, W., Miao, Y., Du, H., Xia, H., Tao, Z., Du, Z., Tang, Y., & Fang, Q. (2025) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2024.114374 · Cited by 7
Metadata
- Authors
- Lammers, T.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2024-04-12
- Volume
- 36
- Issue
- 26
- Pages
- e2312169-e2312169
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W4391910418
- Cited by
- 290
- References
- 170
- FWCI
- 24.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.